Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS
Clinical evidence: The SURMOUNT-1 trial, published in the New England Journal of Medicine (2022), showed that participants receiving tirzepatide at the highest dose (15mg) lost an average of 22.5% of their body weight over 72 weeks roughly 52 pounds
While support systems appear effective, ongoing concerns about future challenges remain, indicating a need for continued dialogue and support for families affected by XLH
Most symptoms are mild, moderate, and often decrease as your body acclimates to the medication
In a similar randomized, double-blind, placebo-controlled clinical trial, Miyanaga et al
Fen Yuan, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
